Cristina Palomo‐Garo

Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

Yolanda Gómez‐Gálvez, Cristina Palomo‐Garo, Javier Fernández‐Ruíz et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2015 · 213 citations

Medicine, Neuroscience, Pharmacology +14

Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ⁹‐THCV in animal models of Parkinson's disease

Concepción García, Cristina Palomo‐Garo, Moisés Garcı́a-Arencibia et al. · British Journal of Pharmacology · 2011 · 208 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson’s disease

Valentina Cinquina, Cristina Palomo‐Garo, Alberto Rábano et al. · Neuroscience Letters · 2014 · 107 citations

Life Sciences, Neuroscience, Pharmacology +16

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

Concepción García, María Gómez‐Cañas, Sonia Burgaz et al. · Journal of Neuroinflammation · 2018 · 64 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Targeting the cannabinoid CB 2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice

Cristina Palomo‐Garo, Yolanda Gómez‐Gálvez, Concepción García et al. · Pharmacological Research · 2016 · 53 citations

Life Sciences, Neuroscience, Pharmacology +15